NZ550479A - A stable dry powder formulation comprising glycopyrrolate and magnesium stearate - Google Patents

A stable dry powder formulation comprising glycopyrrolate and magnesium stearate

Info

Publication number
NZ550479A
NZ550479A NZ550479A NZ55047905A NZ550479A NZ 550479 A NZ550479 A NZ 550479A NZ 550479 A NZ550479 A NZ 550479A NZ 55047905 A NZ55047905 A NZ 55047905A NZ 550479 A NZ550479 A NZ 550479A
Authority
NZ
New Zealand
Prior art keywords
formulation
dry powder
glycopyrrolate
micronised
powder formulation
Prior art date
Application number
NZ550479A
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ550479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NZ550479A publication Critical patent/NZ550479A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ550479A 2004-04-30 2005-04-29 A stable dry powder formulation comprising glycopyrrolate and magnesium stearate NZ550479A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NZ550479A true NZ550479A (en) 2009-11-27

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ550479A NZ550479A (en) 2004-04-30 2005-04-29 A stable dry powder formulation comprising glycopyrrolate and magnesium stearate

Country Status (26)

Country Link
US (1) US20080063719A1 (enExample)
EP (3) EP1755555B1 (enExample)
JP (2) JP5000483B2 (enExample)
KR (1) KR101287919B1 (enExample)
CN (3) CN107252423A (enExample)
AU (2) AU2005237266B2 (enExample)
BR (1) BRPI0510500B8 (enExample)
CA (1) CA2563760C (enExample)
CY (6) CY1113069T1 (enExample)
DK (2) DK2422766T3 (enExample)
ES (2) ES2388289T3 (enExample)
GB (1) GB0409703D0 (enExample)
HU (4) HUE025463T2 (enExample)
IL (2) IL178651A (enExample)
LT (1) LTC2422766I2 (enExample)
LU (2) LU92176I2 (enExample)
MX (2) MXPA06012493A (enExample)
NO (1) NO20065502L (enExample)
NZ (1) NZ550479A (enExample)
PL (2) PL1755555T3 (enExample)
PT (2) PT1755555E (enExample)
RU (1) RU2396943C2 (enExample)
SG (3) SG186673A1 (enExample)
SI (2) SI1755555T1 (enExample)
WO (1) WO2005105043A2 (enExample)
ZA (1) ZA200609350B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20100247658A1 (en) * 2007-12-13 2010-09-30 Gerhard Muhrer Organic compounds
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2552414A4 (en) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
ES2705494T3 (es) 2010-08-31 2019-03-25 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6454323B2 (ja) † 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
HRP20260435T1 (hr) * 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
EP3595631B1 (en) * 2017-03-15 2024-11-27 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006100453A1 (en) * 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
SI2422766T1 (sl) 2015-10-30
CY1116655T1 (el) 2017-03-15
PL1755555T3 (pl) 2012-11-30
PT1755555E (pt) 2012-08-17
NO20065502L (no) 2007-01-24
AU2011200543A8 (en) 2011-03-31
IL223545A0 (en) 2013-02-03
JP2012031209A (ja) 2012-02-16
LU92392I2 (fr) 2015-11-02
CY2015059I1 (el) 2020-05-29
HUS1300006I1 (hu) 2016-07-28
ZA200609350B (en) 2008-04-30
RU2396943C2 (ru) 2010-08-20
LTC2422766I2 (lt) 2020-02-10
CN102008453A (zh) 2011-04-13
CN1964700A (zh) 2007-05-16
ES2546982T3 (es) 2015-09-30
EP1755555B1 (en) 2012-05-23
WO2005105043A3 (en) 2006-05-04
CN107252423A (zh) 2017-10-17
MXPA06012493A (es) 2007-01-29
AU2005237266B2 (en) 2010-11-11
EP2422766A3 (en) 2012-04-25
EP1755555A2 (en) 2007-02-28
LU92176I2 (fr) 2013-05-27
SG10201605001SA (en) 2016-08-30
PT2422766E (pt) 2015-10-12
SG186673A1 (en) 2013-01-30
CY2013012I1 (el) 2015-08-05
HK1095282A1 (en) 2007-05-04
ES2388289T3 (es) 2012-10-11
AU2011200543A1 (en) 2011-03-03
BRPI0510500B1 (pt) 2019-04-24
AU2011200543B2 (en) 2012-11-29
SI1755555T1 (sl) 2012-10-30
CY1113069T1 (el) 2015-08-05
IL223545A (en) 2016-04-21
JP5124718B2 (ja) 2013-01-23
RU2006142322A (ru) 2008-06-20
CY2015060I1 (el) 2020-05-29
HK1167334A1 (en) 2012-11-30
BRPI0510500A (pt) 2007-10-30
US20080063719A1 (en) 2008-03-13
EP2422767A2 (en) 2012-02-29
EP2422766B1 (en) 2015-06-24
JP2007535522A (ja) 2007-12-06
PL2422766T3 (pl) 2015-11-30
HUS1500073I1 (hu) 2016-02-29
CY2014015I1 (el) 2015-12-09
WO2005105043A2 (en) 2005-11-10
MX341426B (es) 2016-08-18
EP2422766A2 (en) 2012-02-29
SG152292A1 (en) 2009-05-29
LU92176I9 (enExample) 2019-01-04
CY2014015I2 (el) 2015-12-09
GB0409703D0 (en) 2004-06-02
KR20070033978A (ko) 2007-03-27
CA2563760A1 (en) 2005-11-10
CA2563760C (en) 2013-07-02
CY2013012I2 (el) 2015-08-05
AU2005237266A1 (en) 2005-11-10
HUS1500072I1 (hu) 2016-02-29
HUE025463T2 (en) 2016-02-29
EP2422767A3 (en) 2012-04-25
BRPI0510500B8 (pt) 2021-05-25
DK1755555T3 (da) 2012-08-20
JP5000483B2 (ja) 2012-08-15
KR101287919B1 (ko) 2013-07-18
IL178651A0 (en) 2007-02-11
IL178651A (en) 2012-12-31
DK2422766T3 (da) 2015-08-31

Similar Documents

Publication Publication Date Title
AU2011200543B2 (en) Pharmaceutical compositions
TWI536988B (zh) 糖基吡咯之新穎用途
JP2016519160A (ja) ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
AU2015314272B2 (en) Formulation comprising glycopyrrolate, method and apparatus
HK1095282B (en) Methods for preparing dry powder compositions of glycopyrrolate
HK1168273A (en) Methods for preparing dry powder compositions of glycopyrrolate
HK1167334B (en) Dry powder compositions of glycopyrrolate and magnesium stearate
HK40035236A (en) Formulation comprising glycopyrrolate, method and apparatus
KR20170070151A (ko) 흡입형 제제
HK1241279A1 (en) Formulation comprising glycopyrrolate, method and apparatus

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20140909

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240330

EXPY Patent expired